Canagliflozin vs Dapagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT01032629 · Phase 3 · completed

The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.

Next expected readout: December 2026 · NCT05427084 (registry estimate)

Reported efficacy

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)

Result source: NCT03170518

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00528372 · Phase 3 · completed

The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)

Result source: NCT01392677

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinDapagliflozin
HbA1c, change-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926
Body weight, change (kg)-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926
HbA1c below 7%42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851
Fasting plasma glucose, change-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898
3-point MACE (% with event)—Not posted · NCT04304261—Not posted · NCT04170998

HbA1c, change

Canagliflozin
-0.4% vs 0.4%−0.8 vs placebo100/300 mg · wk 26 · n 84NCT03170518
41 other results
  • -0.7% vs -0.0% 300 mg · wk 26 · n 229 · Phase 3 · primary NCT01106651
  • -0.4% vs -0.0% 300 mg · wk 26 · n 89 · Phase 3 · primary NCT01064414
  • -1.0% vs -0.3% 300 mg · wk 26 · n 112 · Phase 3 · primary NCT01106690
  • -1.1% vs -0.1% 300 mg · wk 26 · n 152 · Phase 3 · primary NCT01106625
  • -1.0% vs 0.1% 300 mg · wk 26 · n 194 · Phase 3 · primary NCT01081834
  • -1.1% vs -0.5% 300 mg · wk 18 · n 227 · Phase 3 · primary NCT01381900
  • -0.6% vs -0.0% 100 mg · wk 26 · n 239 · Phase 3 · primary NCT01106651
  • -0.3% vs -0.0% 100 mg · wk 26 · n 88 · Phase 3 · primary NCT01064414
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 26 · n 155 · Phase 3 · primary NCT01106625
  • -0.8% vs 0.1% 100 mg · wk 26 · n 191 · Phase 3 · primary NCT01081834
  • -1.0% vs -0.5% 100 mg · wk 18 · n 223 · Phase 3 · primary NCT01381900
  • -1.0% vs -0.1% wk 24 · n 70 · Phase 3 · primary NCT02354235
  • -0.9% vs -0.8% 300 mg · wk 52 · n 474 · Phase 3 · primary NCT00968812
  • -1.0% vs -0.7% 300 mg · wk 52 · n 374 · Phase 3 · primary NCT01137812
  • -1.4% vs -1.3% 300 mg · wk 26 · n 234 · Phase 3 · primary NCT01809327
  • -0.9% vs -0.8% 300 mg · wk 26 · n 360 · Phase 3 · primary NCT01106677
  • -0.8% vs -0.8% 100 mg · wk 52 · n 478 · Phase 3 · primary NCT00968812
  • -1.4% vs -1.3% 100 mg · wk 26 · n 230 · Phase 3 · primary NCT01809327
  • -0.8% vs -0.8% 100 mg · wk 26 · n 365 · Phase 3 · primary NCT01106677
  • -1.8% vs -1.3% wk 26 · n 236 · Phase 3 · primary NCT01809327
  • -1.8% vs -1.3% wk 26 · n 235 · Phase 3 · primary NCT01809327
  • -0.3% vs 0.0% 300 mg · wk 338 · n 1352 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.0% 100 mg · wk 338 · n 1392 · Phase 3 · secondary NCT01032629
  • -0.3% vs 0.7% 100/300 mg · wk 52 · n 84 · Phase 3 · secondary NCT03170518
  • -0.6% vs 0.1% 100/300 mg · wk 12 · n 84 · Phase 3 · secondary NCT03170518
  • -0.9% vs -0.7% 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 300 mg · wk 104 · n 474 · Phase 3 · secondary NCT00968812
  • -0.7% vs -0.7% 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • -0.7% vs -0.6% 100 mg · wk 104 · n 478 · Phase 3 · secondary NCT00968812
  • -0.9% vs -0.2% 300 mg daily · wk 12 · n 60 · Phase 2 · primary NCT00642278
  • -0.8% vs -0.2% 100 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.2% 300 mg twice daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.7% vs -0.2% 200 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.6% vs -0.0% 150 mg Bid · wk 18 · n 91 · Phase 2 · primary NCT01340664
  • -0.5% vs -0.0% 50 mg Bid · wk 18 · n 90 · Phase 2 · primary NCT01340664
  • -0.8% vs -0.2% 50 mg daily · wk 12 · n 62 · Phase 2 · primary NCT00642278
  • -0.9% vs -0.0% wk 26 · n 99 · Phase 4 · primary NCT02025907
  • -1.0% vs 0.1% wk 16 · n 76 · Phase 4 · primary NCT02220920
  • -0.9% vs -1.1% n 76 · Phase 4 · secondary NCT02622113
  • 7.8% vs 8.3% wk 16 · n 15 · Phase 4 · secondary NCT02964585
Dapagliflozin
-0.9% vs -0.2%−0.7 vs placebo10 mg AM · wk 24 · n 65NCT00528372
50 other results
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 73 · Phase 3 · primary NCT00528372
  • -0.9% vs -0.2% 10 mg · wk 24 · n 108 · Phase 3 · primary NCT01392677
  • -0.9% vs -0.3% 10mg · wk 24 · n 192 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 5mg · wk 24 · n 210 · Phase 3 · primary NCT00673231
  • -0.8% vs -0.3% 2.5mg · wk 24 · n 198 · Phase 3 · primary NCT00673231
  • -0.6% vs 0.1% 10 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.7% vs 0.1% 20 mg · wk 12 · n 23 · Phase 2/3 · primary NCT00357370
  • -0.8% vs -0.2% 5 mg AM · wk 24 · n 61 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 63 · Phase 3 · primary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 64 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 62 · Phase 3 · primary NCT00528372
  • -0.8% vs -0.3% 10 mg · wk 24 · n 132 · Phase 3 · primary NCT00528879
  • -0.8% vs -0.1% 10 mg · wk 24 · n 150 · Phase 3 · primary NCT00680745
  • -1.0% vs -0.4% 10MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 5 mg · wk 24 · n 133 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 5 mg · wk 24 · n 142 · Phase 3 · primary NCT00680745
  • -0.8% vs -0.4% 5MG · wk 24 · n 140 · Phase 3 · primary NCT00683878
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 135 · Phase 3 · primary NCT00528879
  • -0.6% vs -0.1% 2.5 mg · wk 24 · n 154 · Phase 3 · primary NCT00680745
  • -0.6% vs 0.4% wk 26 · n 75 · Phase 3 · primary NCT03199053
  • -0.5% vs 0.0% wk 24 · n 223 · Phase 3 · primary NCT00984867
  • -1.2% vs -1.4% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT00643851
  • -2.0% vs -1.4% wk 24 · n 185 · Phase 3 · primary NCT00643851
  • -0.5% vs -0.5% wk 52 · n 400 · Phase 3 · primary NCT00660907
  • -2.0% vs -1.4% wk 24 · n 202 · Phase 3 · primary NCT00859898
  • -1.4% vs -1.4% wk 24 · n 216 · Phase 3 · primary NCT00859898
  • -0.9% vs -0.2% 10 mg AM · wk 24 · n 59 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 10 mg PM · wk 24 · n 60 · Phase 3 · secondary NCT00528372
  • -0.7% vs -0.2% 5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 5 mg PM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -0.6% vs -0.2% 2.5 mg AM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -0.8% vs -0.2% 2.5 mg PM · wk 24 · n 48 · Phase 3 · secondary NCT00528372
  • -0.9% vs -0.3% 10 mg · wk 24 · n 104 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT00528879
  • -0.7% vs -0.3% 2.5 mg · wk 24 · n 118 · Phase 3 · secondary NCT00528879
  • -2.0% vs 0.2% 10 mg AM · wk 24 · n 14 · Phase 3 · secondary NCT00528372
  • -1.2% vs 0.2% 10 mg PM · wk 24 · n 12 · Phase 3 · secondary NCT00528372
  • -1.4% vs -0.5% 5 mg · wk 24 · n 34 · Phase 3 · secondary NCT00528879
  • -0.8% vs 0.0% wk 24 · n 94 · Phase 3 · secondary NCT00984867
  • -2% vs 0.2% 5 mg AM · wk 24 · n 9 · Phase 3 · secondary NCT00528372
  • -1.5% vs 0.2% 5 mg PM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.3% vs 0.2% 2.5 mg AM · wk 24 · n 8 · Phase 3 · secondary NCT00528372
  • -1.4% vs 0.2% 2.5 mg PM · wk 24 · n 11 · Phase 3 · secondary NCT00528372
  • -1.3% vs -0.5% 10 mg · wk 24 · n 18 · Phase 3 · secondary NCT00528879
  • -1.2% vs -0.5% 2.5 mg · wk 24 · n 17 · Phase 3 · secondary NCT00528879
  • -1.7% vs -1.8% 5 mg · wk 24 · n 96 · Phase 3 · secondary NCT00643851
  • -3.0% vs -1.8% wk 24 · n 92 · Phase 3 · secondary NCT00643851
  • -2.6% vs -2.0% wk 24 · n 106 · Phase 3 · secondary NCT00859898
  • -2.1% vs -2.0% wk 24 · n 97 · Phase 3 · secondary NCT00859898
  • -1% vs -0.5% wk 52 · n 56 · Phase 4 · secondary NCT02564926

Body weight, change (kg)

Canagliflozin
-2.9 vs -0.8−2.1 vs placebo300 mg daily · wk 12 · n 62NCT00642278
8 other results
  • -1.5 vs 0.1 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -2.3 vs -0.8 100 mg daily · wk 12 · n 64 · Phase 2 · secondary NCT00642278
  • -1.0 vs 0.1 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -2.9 vs -0.8 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -2.3 vs -0.8 200 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -2.0 vs -0.8 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -3.5 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
  • -6 vs -1.9 wk 16 · n 15 · Phase na · secondary NCT02324842
Dapagliflozin
-3.2 vs -2.2−1 vs placebo10 mg AM · wk 24 · n 69NCT00528372
40 other results
  • -3.0 vs -2.2 10 mg PM · wk 24 · n 74 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg AM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 10 mg PM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • -2.6 vs -0.6 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.7 vs 0.0 10mg · wk 24 · n 192 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 5mg · wk 24 · n 210 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.0 2.5mg · wk 24 · n 198 · Phase 3 · secondary NCT00673231
  • -2.8 vs -2.2 5 mg AM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • -3.5 vs -2.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -2.9 vs -2.4 5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -3.7 vs -2.4 5 mg PM · wk 24 · n 57 · Phase 3 · secondary NCT00528372
  • -3.3 vs -2.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -3.8 vs -2.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -3.4 vs -2.4 2.5 mg AM · wk 24 · n 54 · Phase 3 · secondary NCT00528372
  • -4.3 vs -2.4 2.5 mg PM · wk 24 · n 53 · Phase 3 · secondary NCT00528372
  • -2.9 vs -0.9 10 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • -3.1 vs -1.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT00528879
  • -2.3 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT00680745
  • -2.5 vs -0.8 10 mg · wk 24 · n 99 · Phase 3 · secondary NCT00680745
  • -0.1 vs 1.6 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.1 vs 1.8 10MG · wk 24 · n 113 · Phase 3 · secondary NCT00683878
  • -3.0 vs -0.9 5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -3.2 vs -1.0 5 mg · wk 24 · n 111 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.7 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.7 vs -0.8 5 mg · wk 24 · n 97 · Phase 3 · secondary NCT00680745
  • 0.1 vs 1.6 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 0.3 vs 1.8 5MG · wk 24 · n 101 · Phase 3 · secondary NCT00683878
  • -2.2 vs -0.9 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -2.4 vs -1.0 2.5 mg · wk 24 · n 120 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.7 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -1.2 vs -0.8 2.5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00680745
  • -2.1 vs -0.3 wk 24 · n 223 · Phase 3 · secondary NCT00984867
  • -2.6 vs -1.3 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -2.9 vs -1.5 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT00643851
  • -2.7 vs -1.3 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.0 vs -1.5 wk 24 · n 142 · Phase 3 · secondary NCT00643851
  • -3.2 vs 1.4 wk 52 · n 400 · Phase 3 · secondary NCT00660907
  • -3.3 vs -1.4 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.7 vs -1.4 wk 24 · n 219 · Phase 3 · secondary NCT00859898
  • -2.4 vs 1.3 wk 52 · n 56 · Phase 4 · secondary NCT02564926

HbA1c below 7%

Canagliflozin
42.8% vs 43%vs Metformin XR300 mg · wk 26 · n 215NCT01809327
6 other results
  • 38.8% vs 43% 100 mg · wk 26 · n 206 · Phase 3 · secondary NCT01809327
  • 56.8% vs 43% wk 26 · n 213 · Phase 3 · secondary NCT01809327
  • 49.6% vs 43% wk 26 · n 224 · Phase 3 · secondary NCT01809327
  • 57.1% vs 31.5% 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • 47.8% vs 31.5% 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • 32.3% vs 12.2% wk 26 · n 96 · Phase 4 · secondary NCT02025907
Dapagliflozin
50.8% vs 31.6%+19.2 vs placebo10 mg AM · wk 24 · n 65NCT00528372
17 other results
  • 51.6% vs 31.6% 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • 31.8% vs 11.1% 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • 44.2% vs 31.6% 5 mg AM · wk 24 · n 61 · Phase 3 · secondary NCT00528372
  • 44% vs 31.6% 5 mg PM · wk 24 · n 63 · Phase 3 · secondary NCT00528372
  • 41.3% vs 31.6% 2.5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • 51.4% vs 31.6% 2.5 mg PM · wk 24 · n 62 · Phase 3 · secondary NCT00528372
  • 40.6% vs 25.9% 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • 31.7% vs 13% 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • 38.8% vs 22.4% 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 37.5% vs 25.9% 5 mg · wk 24 · n 133 · Phase 3 · secondary NCT00528879
  • 30.3% vs 13% 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • 32.5% vs 22.4% 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • 33% vs 25.9% 2.5 mg · wk 24 · n 135 · Phase 3 · secondary NCT00528879
  • 26.8% vs 13% 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • 26.6% vs 10% wk 26 · n 64 · Phase 3 · secondary NCT03199053
  • 22.5% vs 34.6% 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT00643851
  • 52.4% vs 34.6% wk 24 · n 185 · Phase 3 · secondary NCT00643851

Fasting plasma glucose, change

Canagliflozin
-0.6 vs 0.2−0.7 vs placebo300 mg · wk 338 · n 1377NCT01032629
34 other results
  • -0.4 vs 0.2 100 mg · wk 338 · n 1410 · Phase 3 · secondary NCT01032629
  • -1.1 vs 0.4 300 mg · wk 26 · n 229 · Phase 3 · secondary NCT01106651
  • -0.7 vs 0.0 300 mg · wk 26 · n 88 · Phase 3 · secondary NCT01064414
  • -1.8 vs 0.1 300 mg · wk 26 · n 112 · Phase 3 · secondary NCT01106690
  • -1.7 vs 0.2 300 mg · wk 26 · n 152 · Phase 3 · secondary NCT01106625
  • -1.9 vs 0.5 300 mg · wk 26 · n 192 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 300 mg · wk 18 · n 227 · Phase 3 · secondary NCT01381900
  • -1 vs 0.4 100 mg · wk 26 · n 239 · Phase 3 · secondary NCT01106651
  • -0.8 vs 0.0 100 mg · wk 26 · n 90 · Phase 3 · secondary NCT01064414
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -1.0 vs 0.2 100 mg · wk 26 · n 155 · Phase 3 · secondary NCT01106625
  • -1.5 vs 0.5 100 mg · wk 26 · n 188 · Phase 3 · secondary NCT01081834
  • -0.1 vs -0.0 100 mg · wk 18 · n 223 · Phase 3 · secondary NCT01381900
  • -1.9 vs 0.2 wk 24 · n 69 · Phase 3 · secondary NCT02354235
  • -2.1 vs -1.1 300 mg · wk 26 · n 360 · Phase 3 · secondary NCT01106677
  • -1.9 vs -1.0 300 mg · wk 52 · n 360 · Phase 3 · secondary NCT01106677
  • -1.7 vs -0.3 300 mg · wk 52 · n 373 · Phase 3 · secondary NCT01137812
  • -1.5 vs -1.1 100 mg · wk 26 · n 365 · Phase 3 · secondary NCT01106677
  • -1.4 vs -1.0 100 mg · wk 52 · n 365 · Phase 3 · secondary NCT01106677
  • 9.7 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • 10.0 vs 9.8 wk 16 · n 15 · Phase na · primary NCT02324842
  • -1.4 vs 0.2 300 mg daily · wk 12 · n 61 · Phase 2 · secondary NCT00642278
  • -1.3 vs -0.4 300 mg · wk 6 · n 56 · Phase 4 · secondary NCT01939496
  • -1.4 vs 0.2 100 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -0.0 vs -0.4 100 mg · wk 6 · n 57 · Phase 4 · secondary NCT01939496
  • -1.3 vs 0.2 300 mg twice daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -1.5 vs 0.2 200 mg daily · wk 12 · n 62 · Phase 2 · secondary NCT00642278
  • -0.9 vs 0.5 150 mg Bid · wk 18 · n 91 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.5 50 mg Bid · wk 18 · n 90 · Phase 2 · secondary NCT01340664
  • -0.9 vs 0.2 50 mg daily · wk 12 · n 63 · Phase 2 · secondary NCT00642278
  • -1.6 vs -0.1 wk 26 · n 103 · Phase 4 · secondary NCT02025907
  • -1.9 vs -0.1 wk 16 · n 75 · Phase 4 · secondary NCT02220920
  • -1.8 vs -1.8 n 75 · Phase 4 · secondary NCT02622113
  • 7.9 vs 8.8 wk 16 · n 15 · Phase 4 · secondary NCT02964585
Dapagliflozin
-1.3 vs 0.2−1.5 vs placebowk 24 · n 222NCT00984867
34 other results
  • -1.6 vs -0.2 10 mg AM · wk 24 · n 70 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.2 10 mg PM · wk 24 · n 73 · Phase 3 · secondary NCT00528372
  • -1.9 vs -0.0 10 mg · wk 24 · n 108 · Phase 3 · secondary NCT01392677
  • -1.2 vs 0.2 10mg · wk 24 · n 183 · Phase 3 · secondary NCT00673231
  • -1.0 vs 0.2 5mg · wk 24 · n 204 · Phase 3 · secondary NCT00673231
  • 0.1 vs 1.0 10 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -0.9 vs -0.1 10 mg AM · wk 1 · n 65 · Phase 3 · secondary NCT00528372
  • -0.7 vs 0.2 2.5mg · wk 24 · n 190 · Phase 3 · secondary NCT00673231
  • -1.1 vs -0.1 10 mg PM · wk 1 · n 60 · Phase 3 · secondary NCT00528372
  • -0.5 vs 1.0 20 mg · wk 12 · n 23 · Phase 2/3 · secondary NCT00357370
  • -1.3 vs -0.2 5 mg AM · wk 24 · n 64 · Phase 3 · secondary NCT00528372
  • -1.5 vs -0.2 5 mg PM · wk 24 · n 66 · Phase 3 · secondary NCT00528372
  • -0.9 vs -0.1 5 mg AM · wk 1 · n 56 · Phase 3 · secondary NCT00528372
  • -1.0 vs -0.1 5 mg PM · wk 1 · n 54 · Phase 3 · secondary NCT00528372
  • -0.8 vs -0.2 2.5 mg AM · wk 24 · n 65 · Phase 3 · secondary NCT00528372
  • -1.4 vs -0.2 2.5 mg PM · wk 24 · n 67 · Phase 3 · secondary NCT00528372
  • -0.2 vs -0.1 2.5 mg AM · wk 1 · n 57 · Phase 3 · secondary NCT00528372
  • -1.6 vs -0.1 10 mg · wk 24 · n 150 · Phase 3 · secondary NCT00680745
  • -0.8 vs -0.1 2.5 mg PM · wk 1 · n 48 · Phase 3 · secondary NCT00528372
  • -1.3 vs -0.3 10 mg · wk 24 · n 132 · Phase 3 · secondary NCT00528879
  • -1.6 vs -0.3 10MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.9 vs 0.1 10 mg · wk 1 · n 115 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.3 5 mg · wk 24 · n 136 · Phase 3 · secondary NCT00528879
  • -1.2 vs -0.1 5 mg · wk 24 · n 142 · Phase 3 · secondary NCT00680745
  • -1.4 vs -0.3 5MG · wk 24 · n 140 · Phase 3 · secondary NCT00683878
  • -0.7 vs 0.1 5 mg · wk 1 · n 121 · Phase 3 · secondary NCT00528879
  • -1.0 vs -0.3 2.5 mg · wk 24 · n 137 · Phase 3 · secondary NCT00528879
  • -0.9 vs -0.1 2.5 mg · wk 24 · n 154 · Phase 3 · secondary NCT00680745
  • -0.3 vs 0.1 2.5 mg · wk 1 · n 120 · Phase 3 · secondary NCT00528879
  • -0.6 vs 0.5 wk 26 · n 75 · Phase 3 · secondary NCT03199053
  • -2.3 vs -1.9 5 mg · wk 24 · n 203 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 192 · Phase 3 · secondary NCT00643851
  • -3.4 vs -1.9 wk 24 · n 209 · Phase 3 · secondary NCT00859898
  • -2.6 vs -1.9 wk 24 · n 216 · Phase 3 · secondary NCT00859898

3-point MACE (% with event)

Canagliflozin
—Not posted · NCT04304261
Dapagliflozin
—Not posted · NCT04170998
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Canagliflozin: 13 of 13 rows · Dapagliflozin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozin
Rows use multiple source trials
Dapagliflozin
Rows use multiple source trials
BMI
absolute change · kg
-0.7 vs -0.5 placebo kg @ 52wk100/300 mga,b,c
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.91 vs 0.46 Glimepiride kg @ 52wka,b,c
NCT02564926 · Phase 4 · registry result, not featured evidence
Body Fat
percent change · % of baseline
-1.18% (n=60) vs 0.02% (n=50) placebo @ 26wk300 mgd,a,b,c,e
NCT01106651 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.04% (n=56) vs 0.02% (n=50) placebo @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-1.21% (n=56) vs 0.73% (n=56) Glimepiride @ 52wka,b,c,e
NCT02564926 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-4.79 mmol/L @ 26wk*300 mgd,b,c
NCT01081834 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -86.3 mg/dL as posted
show 1 more dose
-4.53 mmol/L @ 26wk*100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -81.7 mg/dL as posted
-1.62 mmol/L @ 26wk10 mgd,b,c
NCT03199053 · Phase 3
show 1 more dose
-0.98 mmol/L @ 26wk5 mg
NCT03199053 · Phase 3
HbA1c
absolute value · percentage points
8.2% (n=15) vs 8.4% (n=15) Liraglutide @ 16wkd,f,b,g
NCT02324842 · Phase na · registry result, not featured evidence
show 1 more dose
8.1% (n=15) vs 8.4% (n=15) Liraglutide @ 16wk
NCT02324842 · Phase na · registry result, not featured evidence · combination
7.4% (n=31) vs 8% (n=31) placebo @ 52wkf,b,g
NCT03782259 · Phase 4 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.56% (n=43) @ 26wk300 mgd,b,c
NCT01081834 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.13% (n=46) @ 26wk100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-0.74% (n=19) @ 26wk10 mgd,b,c
NCT03199053 · Phase 3
show 1 more dose
-0.71% (n=21) @ 26wk5 mg
NCT03199053 · Phase 3
HbA1c Less Than 7
absolute value · percentage points
47.6% (n=374) vs 35.3% (n=365) Sitagliptin @ 52wk300 mgb,h
NCT01137812 · Phase 3 · registry result, not featured evidence
31.7% (n=216) vs 35.5% (n=203) Metformin XR @ 24wkd,b,h
NCT00859898 · Phase 3
show 1 more dose
46.6% (n=202) vs 35.5% (n=203) Metformin XR @ 24wk
NCT00859898 · Phase 3 · combination
PPG 2h Change mg/dL
absolute change · mmol/L
-3.34 vs -0.51 placebo mmol/L @ 24wk*b
NCT02354235 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -60.1 mg/dL as posted
-3.75 vs -0.78 placebo mmol/L @ 24wk*10MGd,b
NCT00683878 · Phase 3 · combination · converted to mmol/L from -67.5 mg/dL as posted
show 1 more dose
-3.61 vs -0.78 placebo mmol/L @ 24wk*5MG
NCT00683878 · Phase 3 · combination · converted to mmol/L from -65.1 mg/dL as posted
SBP
absolute change · mmHg
-4.65 vs -0.66 Sitagliptin mmHg @ 52wk300 mgd,a,b,c
NCT01106677 · Phase 3 · registry result, not featured evidence
show 1 more dose
-3.53 vs -0.66 Sitagliptin mmHg @ 52wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.18 vs 4.63 Glimepiride mmHg @ 52wka,b,c
NCT02564926 · Phase 4 · registry result, not featured evidence
Seated SBP
absolute change · mmHg
0 vs 1.5 placebo mmHg @ 52wk100/300 mgi,c,j
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-4.04 vs -0.27 placebo mmHg @ 8wk10 mgi,c,j
NCT01392677 · Phase 3 · combination
1 other source trial
-5.98 vs -5.12 placebo mmHg @ 8wk
NCT00984867 · Phase 3
Dropout rate
6.1%300 mgk
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
7%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
29%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
0.7%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
1.2%
NCT01989754 · Phase 4 · registry result, not featured evidence
13.2%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02025907 · Phase 4 · registry result, not featured evidence
3.9%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
3.6%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
5.3%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
9.2%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
11%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
10.5%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
5.1%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
24.6%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
23.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
5.3%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
4%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
7.9%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
16.7%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.4%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
8%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
12%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
12.5%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
17.3%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
17.8%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
32.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
14%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
8.6%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
12.5%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
10.9%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
13.8%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
7.8%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
13.3%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
18.6%10 mg AMl
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
14.5%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.8%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.8%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
16.2%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.7%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
0%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
14.2%Dapagliflozin
NCT00859898 · Phase 3
13.3%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
16.3%5 mg
NCT00643851 · Phase 3
8.8%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
11.9%10 mg
NCT00528879 · Phase 3 · combination
10.9%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
12.4%2.5 mg
NCT00528879 · Phase 3 · combination
20.7%
NCT00660907 · Phase 3 · combination
6.6%10 mg
NCT00680745 · Phase 3 · combination
9%5 mg
NCT00680745 · Phase 3 · combination
9.1%2.5 mg
NCT00680745 · Phase 3 · combination
7.3%10 mg
NCT01392677 · Phase 3 · combination
10%10MG
NCT00683878 · Phase 3 · combination
11.3%5MG
NCT00683878 · Phase 3 · combination
7.6%
NCT00984867 · Phase 3
9.2%10mg
NCT00673231 · Phase 3
12.3%5mg
NCT00673231 · Phase 3
10.9%2.5mg
NCT00673231 · Phase 3
2.5%10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
6.2%Dapagliflozin
NCT03199053 · Phase 3 · background therapy
1.3%10 mg
NCT01730534 · Phase 3
16.7%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
16.7%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
12.9%
NCT03782259 · Phase 4 · registry result, not featured evidence
16%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
7.4%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
7.7%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
8.3%
NCT03074630 · Phase 4 · registry result, not featured evidence
13.3%
NCT02564926 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—300 mgk
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
—100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
—300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
—100 mg
NCT02065791 · Phase 3
—
NCT02964585 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—
NCT01989754 · Phase 4 · registry result, not featured evidence
5.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
0.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
1.3%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.3%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
3.4%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
1.7%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
9.7%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.1%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
4.4%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
0.9%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
1.6%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
7.5%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.1%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
3.1%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
4.7%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
3.1%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
—Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
—Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
8.6%10 mg AMl
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
4.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.1%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
—20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.1%Dapagliflozin
NCT00859898 · Phase 3
1.9%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
3%5 mg
NCT00643851 · Phase 3
1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
3%10 mg
NCT00528879 · Phase 3 · combination
1.5%5 mg
NCT00528879 · Phase 3 · combination
—5.0 mg
NCT00528879 · Phase 3 · combination
2.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.1%
NCT00660907 · Phase 3 · combination
2%10 mg
NCT00680745 · Phase 3 · combination
2.1%5 mg
NCT00680745 · Phase 3 · combination
3.2%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
2.1%10MG
NCT00683878 · Phase 3 · combination
2.1%5MG
NCT00683878 · Phase 3 · combination
3.1%
NCT00984867 · Phase 3
3.1%10mg
NCT00673231 · Phase 3
4.2%5mg
NCT00673231 · Phase 3
2.5%2.5mg
NCT00673231 · Phase 3
—10mg QD
NCT02413398 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3
—10 mg
NCT03199053 · Phase 3 · combination
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
—10 mg
NCT01730534 · Phase 3
—Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
—Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
—T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
—Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
—Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
4%
NCT02235298 · Phase 4 · registry result, not featured evidence
—
NCT02796170 · Phase 4 · registry result, not featured evidence
—10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
—
NCT02973477 · Phase 4 · registry result, not featured evidence
—10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
—
NCT02433678 · Phase 4 · registry result, not featured evidence
—10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
—
NCT02564926 · Phase 4 · registry result, not featured evidence
Serious AEs
42.1%300 mgk
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 72 more results
41.6%100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.7%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.4%300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.7%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.9%300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
10.4%100 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
33.5%100 mg
NCT02065791 · Phase 3
0%
NCT02964585 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
17.6%
NCT02920918 · Phase 4 · registry result, not featured evidence
24.6%
NCT01989754 · Phase 4 · registry result, not featured evidence
9.3%
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
7%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
1.9%
NCT02025907 · Phase 4 · registry result, not featured evidence
4%
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
0%300 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT01939496 · Phase 4 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.4%
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
2.9%300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
1.7%Canagliflozin 300 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
3%Canagliflozin 100 mg + Metformin X
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
—300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
18.2%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
3.4%300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
16.6%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
1.8%300 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
2.2%100 mg
NCT01381900 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.2%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
23.6%300 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
11.1%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
20%100 mg
NCT01064414 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
7.1%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
2.7%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
3.3%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.8%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
5.1%300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
3.2%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
4.5%100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
2.3%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
1%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
2.5%300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
4.1%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
5.6%100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
6.4%300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
3.2%150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
0%50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
1.6%300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.5%200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
1.6%50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
6.7%Canagliflozin
NCT02324842 · Phase na · registry result, not featured evidence
0%Canagliflozin Plus Liraglutide
NCT02324842 · Phase na · registry result, not featured evidence · combination
1.4%10 mg AMl
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
3.9%10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—10 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
7.4%5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.4%2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%10 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
4.2%20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
2.3%Dapagliflozin
NCT00859898 · Phase 3
1.4%Dapagliflozin + Metformin XR
NCT00859898 · Phase 3 · combination
4.4%5 mg
NCT00643851 · Phase 3
3.1%Dapagliflozin 5 mg + Metformin XR
NCT00643851 · Phase 3 · combination
10.4%10 mg
NCT00528879 · Phase 3 · combination
—5 mg
NCT00528879 · Phase 3 · combination
6.6%5.0 mg
NCT00528879 · Phase 3 · combination
10.9%2.5 mg
NCT00528879 · Phase 3 · combination
8.6%
NCT00660907 · Phase 3 · combination
6%10 mg
NCT00680745 · Phase 3 · combination
6.9%5 mg
NCT00680745 · Phase 3 · combination
7.1%2.5 mg
NCT00680745 · Phase 3 · combination
0.9%10 mg
NCT01392677 · Phase 3 · combination
1.4%10MG
NCT00683878 · Phase 3 · combination
2.8%5MG
NCT00683878 · Phase 3 · combination
4.4%
NCT00984867 · Phase 3
7.1%10mg
NCT00673231 · Phase 3
4.7%5mg
NCT00673231 · Phase 3
7.4%2.5mg
NCT00673231 · Phase 3
5.6%10mg QD
NCT02413398 · Phase 3
0%10 mg
NCT03199053 · Phase 3
4.8%10 mg
NCT03199053 · Phase 3
0%10 mg
NCT03199053 · Phase 3 · combination
1.2%5 mg
NCT03199053 · Phase 3
0%5 mg
NCT03199053 · Phase 3
9.1%5 mg
NCT03199053 · Phase 3
—Dapagliflozin
NCT03199053 · Phase 3 · background therapy
37.4%10 mg
NCT01730534 · Phase 3
0%Dapagliflozin/Hyperfiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Dapagliflozin/Normofiltration
NCT02911792 · Phase 4 · registry result, not featured evidence
0%Normal Glucose Tolerance (NGT) on
NCT02981966 · Phase 4 · registry result, not featured evidence
0%T2DM Individuals on Dapagliflozin
NCT02981966 · Phase 4 · registry result, not featured evidence
0%Byetta / Bydureon
NCT02981069 · Phase 4 · registry result, not featured evidence
0%Byetta/Bydureon Plus Dapagliflozin
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
—
NCT03782259 · Phase 4 · registry result, not featured evidence
0%
NCT02235298 · Phase 4 · registry result, not featured evidence
0%
NCT02796170 · Phase 4 · registry result, not featured evidence
0%10mg
NCT03338855 · Phase 4 · registry result, not featured evidence
2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
0%10 mg
NCT03387683 · Phase 4 · registry result, not featured evidence
0%
NCT02433678 · Phase 4 · registry result, not featured evidence
0%10mg Once Daily
NCT02682563 · Phase 4 · registry result, not featured evidence
—
NCT03074630 · Phase 4 · registry result, not featured evidence
10%
NCT02564926 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
300 mgk
hypoglycaemia 14.6% (placebo 12.1%)
nasopharyngitis 14.1% (placebo 15.3%)
urinary tract infection 11% (placebo 8.9%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 59 more results
100 mg
nasopharyngitis 15.6% (placebo 15.3%)
hypoglycaemia 12.5% (placebo 12.1%)
upper respiratory tract infection 10.9% (placebo 11.3%)
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 11.3%
diarrhoea 8%
upper respiratory tract infection 7.8%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
nasopharyngitis 7.6%
diarrhoea 6.8%
upper respiratory tract infection 5.6%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 9.7%
urinary tract infection 9.1%
upper respiratory tract infection 7.5%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
nasopharyngitis 6.8%
back pain 6%
urinary tract infection 5.4%
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
300 mg
urinary tract infection 29.4% (placebo 4.6%)
urinary tract infection 29.4% (placebo 4.6%)
nausea 11.8% (placebo 1.1%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
headache 11.9% (placebo 3.4%)
headache 11.9% (placebo 3.4%)
nasopharyngitis 11.9% (placebo 5.7%)
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
100 mg
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
300 mg
fatigue 3.2%
diarrhoea 1.6%
discomfort 1.6%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 17.6%
hypotensive event 11.8%
arrhythmic events 5.9%
NCT02920918 · Phase 4 · registry result, not featured evidence
balanoposthitis 3.2% (placebo 0.9%)
NCT01989754 · Phase 4 · registry result, not featured evidence
blood glucose decreased 40% (placebo 23.9%)
hypoglycaemia 38.7% (placebo 32.8%)
nasopharyngitis 34.7% (placebo 25.4%)
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
gastroenteritis 9.9%
hypoglycaemia 9.9%
NCT02227849 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 5.6% (placebo 5.6%)
back pain 2.8% (placebo 0.9%)
depression 2.8% (placebo 0%)
NCT02025907 · Phase 4 · registry result, not featured evidence
blood glucose decreased 26.7% (placebo 16.9%)
hypoglycaemia 25.3% (placebo 21.1%)
nasopharyngitis 16% (placebo 18.3%)
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
300 mg
pollakiuria 5.4% (placebo 1.8%)
nasopharyngitis 0% (placebo 0%)
NCT01939496 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 5.3% (placebo 0%)
pollakiuria 1.8% (placebo 1.8%)
NCT01939496 · Phase 4 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 18.6% (placebo 16.2%)
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 3.8%
upper respiratory tract infection 2.5%
back pain 2.1%
NCT01809327 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 3.8%
glomerular filtration rate decreased 2.5%
influenza 2.5%
NCT01809327 · Phase 3 · registry result, not featured evidence
diarrhoea 4.2%
headache 3%
influenza 3%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 4.2%
headache 3.8%
influenza 3.4%
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 18.6% (placebo 15.2%)
hypoglycaemia 15.3% (placebo 19.8%)
urinary tract infection 14.8% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 9.7% (placebo 19.8%)
nasopharyngitis 8.1% (placebo 15.2%)
urinary tract infection 7.2% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 18.7% (placebo 15.2%)
hypoglycaemia 15.4% (placebo 19.8%)
urinary tract infection 13.3% (placebo 8.9%)
NCT01106651 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 10.4% (placebo 19.8%)
nasopharyngitis 9.5% (placebo 15.2%)
influenza 5.8% (placebo 7.6%)
NCT01106651 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 7.5% (placebo 4%)
upper respiratory tract infection 5.7% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 9% (placebo 4%)
upper respiratory tract infection 3.1% (placebo 6.2%)
NCT01381900 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 11.2% (placebo 4.4%)
nasopharyngitis 7.9% (placebo 11.1%)
urinary tract infection 7.9% (placebo 5.6%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 22.5% (placebo 4.4%)
urinary tract infection 13.5% (placebo 5.6%)
nasopharyngitis 10.1% (placebo 11.1%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 14.4% (placebo 4.4%)
arthralgia 4.4% (placebo 2.2%)
bronchitis 4.4% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
100 mg
hypoglycaemia 20% (placebo 4.4%)
arthralgia 5.6% (placebo 2.2%)
bronchitis 5.6% (placebo 3.3%)
NCT01064414 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 9.6% (placebo 5.2%)
pollakiuria 6.1% (placebo 0.9%)
arthralgia 5.3% (placebo 1.7%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.2% (placebo 5.2%)
arthralgia 7.9% (placebo 1.7%)
urinary tract infection 7.9% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 8% (placebo 6.1%)
back pain 7.1% (placebo 2.6%)
nasopharyngitis 5.3% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 12.4% (placebo 6.1%)
nasopharyngitis 9.7% (placebo 5.2%)
back pain 8.8% (placebo 2.6%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 4.9%
upper respiratory tract infection 4.9%
urinary tract infection 3.5%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.3%
upper respiratory tract infection 6.3%
urinary tract infection 4.6%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
pollakiuria 5.7%
urinary tract infection 4.9%
nasopharyngitis 4.1%
NCT01106677 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 7.3%
pollakiuria 5.7%
headache 5.2%
NCT01106677 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 6.4% (placebo 3.2%)
hypoglycaemia 5.8% (placebo 3.8%)
nasopharyngitis 5.1% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 7.1% (placebo 3.2%)
hypoglycaemia 7.1% (placebo 3.8%)
nasopharyngitis 5.8% (placebo 2.6%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 10.8% (placebo 6.4%)
hypoglycaemia 7% (placebo 3.8%)
urinary tract infection 5.7% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 13.4% (placebo 6.4%)
hypoglycaemia 8.3% (placebo 3.8%)
urinary tract infection 7.6% (placebo 5.1%)
NCT01106625 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 6.8% (placebo 5.2%)
pain in extremity 6.8% (placebo 0%)
urinary tract infection 4.5% (placebo 4.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 8.1% (placebo 5.2%)
back pain 6.1% (placebo 3.1%)
headache 6.1% (placebo 3.6%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 10.2% (placebo 5.2%)
headache 8.6% (placebo 3.6%)
back pain 7.6% (placebo 3.1%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
urinary tract infection 6.4% (placebo 4.2%)
nasopharyngitis 4.3% (placebo 5.2%)
pain in extremity 2.1% (placebo 0%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 7.2% (placebo 3.6%)
urinary tract infection 7.2% (placebo 4.2%)
nasopharyngitis 5.1% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
100 mg
headache 9.7% (placebo 3.6%)
urinary tract infection 8.2% (placebo 4.2%)
nasopharyngitis 7.2% (placebo 5.2%)
NCT01081834 · Phase 3 · registry result, not featured evidence
300 mg
hypoglycaemia 17.5%
nasopharyngitis 8.8%
upper respiratory tract infection 8.8%
NCT01137812 · Phase 3 · registry result, not featured evidence
300 mg daily
headache 4.7% (placebo 3.1%)
nausea 4.7% (placebo 0%)
abdominal pain upper 3.1% (placebo 1.5%)
NCT00642278 · Phase 2 · registry result, not featured evidence
100 mg daily
headache 7.8% (placebo 3.1%)
urinary tract infection 3.1% (placebo 6.2%)
vulvovaginal mycotic infection 3.1% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
300 mg twice daily
nausea 7.8% (placebo 0%)
abdominal pain upper 6.3% (placebo 1.5%)
urinary tract infection 4.7% (placebo 6.2%)
NCT00642278 · Phase 2 · registry result, not featured evidence
200 mg daily
urinary tract infection 9.2% (placebo 6.2%)
vulvovaginal mycotic infection 6.2% (placebo 0%)
headache 3.1% (placebo 3.1%)
NCT00642278 · Phase 2 · registry result, not featured evidence
50 mg daily
nasopharyngitis 7.8% (placebo 3.1%)
vulvovaginal mycotic infection 6.3% (placebo 0%)
nausea 4.7% (placebo 0%)
NCT00642278 · Phase 2 · registry result, not featured evidence
urinary frequency increased 86.7%
dry mouth 26.7%
light-headedness/dizziness 26.7%
NCT02324842 · Phase na · registry result, not featured evidence
nausea 53.3%
dry mouth 40%
constipation 33.3%
NCT02324842 · Phase na · registry result, not featured evidence · combination
10 mg AMl
nasopharyngitis 14.3% (placebo 9.3%)
arthralgia 8.6% (placebo 4%)
headache 8.6% (placebo 12%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 42 more results
10 mg PM
headache 13.2% (placebo 12%)
upper respiratory tract infection 11.8% (placebo 5.3%)
back pain 9.2% (placebo 6.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg AM
pharyngitis 9.4% (placebo 8%)
arthralgia 7.8% (placebo 4%)
headache 7.8% (placebo 12%)
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
5 mg PM
headache 16.2% (placebo 12%)
nasopharyngitis 13.2% (placebo 9.3%)
arthralgia 11.8% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg AM
nasopharyngitis 16.9% (placebo 9.3%)
influenza 10.8% (placebo 4%)
arthralgia 9.2% (placebo 4%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg PM
nasopharyngitis 16.4% (placebo 9.3%)
abdominal pain 9% (placebo 2.7%)
dizziness 9% (placebo 2.7%)
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
back pain 12.5% (placebo 8.7%)
headache 12.5% (placebo 8.7%)
fatigue 8.3% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
20 mg
nausea 12.5% (placebo 4.3%)
pollakiuria 12.5% (placebo 17.4%)
vomiting 12.5% (placebo 0%)
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
urinary tract infection 7.8%
vulvovaginal mycotic infection 5%
diarrhoea 2.7%
NCT00859898 · Phase 3
diarrhoea 7.1%
vulvovaginal mycotic infection 3.3%
urinary tract infection 2.8%
NCT00859898 · Phase 3 · combination
5 mg
dyslipidaemia 5.4%
upper respiratory tract infection 4.9%
urinary tract infection 4.4%
NCT00643851 · Phase 3
diarrhoea 7.7%
nausea 5.7%
upper respiratory tract infection 5.2%
NCT00643851 · Phase 3 · combination
10 mg
back pain 13.3% (placebo 8%)
influenza 12.6% (placebo 10.9%)
diarrhoea 11.9% (placebo 7.3%)
NCT00528879 · Phase 3 · combination
5.0 mg
influenza 14.6% (placebo 10.9%)
headache 9.5% (placebo 5.8%)
arthralgia 7.3% (placebo 5.1%)
NCT00528879 · Phase 3 · combination
2.5 mg
influenza 13.9% (placebo 10.9%)
nasopharyngitis 11.7% (placebo 8.8%)
back pain 8% (placebo 8%)
NCT00528879 · Phase 3 · combination
nasopharyngitis 10.6%
hypertension 7.4%
influenza 7.4%
NCT00660907 · Phase 3 · combination
10 mg
hypoglycemia 7.9% (placebo 4.8%)
nasopharyngitis 3.3% (placebo 2.7%)
hypertension 1.3% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
5 mg
hypoglycemia 6.9% (placebo 4.8%)
nasopharyngitis 5.5% (placebo 2.7%)
hypertension 1.4% (placebo 4.1%)
NCT00680745 · Phase 3 · combination
2.5 mg
hypoglycemia 7.1% (placebo 4.8%)
hypertension 5.2% (placebo 4.1%)
nasopharyngitis 1.9% (placebo 2.7%)
NCT00680745 · Phase 3 · combination
10 mg
urinary tract infection 4.6% (placebo 6.4%)
NCT01392677 · Phase 3 · combination
10MG
dyslipidaemia 9.3% (placebo 4.3%)
nasopharyngitis 7.9% (placebo 3.6%)
diarrhoea 6.4% (placebo 4.3%)
NCT00683878 · Phase 3 · combination
5MG
upper respiratory tract infection 6.4% (placebo 5.8%)
dyslipidaemia 5.7% (placebo 4.3%)
nasopharyngitis 5% (placebo 3.6%)
NCT00683878 · Phase 3 · combination
nasopharyngitis 4% (placebo 6.2%)
NCT00984867 · Phase 3
10mg
hypoglycemia 44.9% (placebo 42.1%)
nasopharyngitis 8.7% (placebo 11.2%)
urinary tract infection 5.6% (placebo 3%)
NCT00673231 · Phase 3
5mg
hypoglycemia 47.6% (placebo 42.1%)
nasopharyngitis 13.7% (placebo 11.2%)
hypertension 6.1% (placebo 8.1%)
NCT00673231 · Phase 3
2.5mg
hypoglycemia 55% (placebo 42.1%)
nasopharyngitis 13.9% (placebo 11.2%)
hypertension 5.4% (placebo 8.1%)
NCT00673231 · Phase 3
10 mg
abdominal pain 4.8% (placebo 2.6%)
abdominal pain upper 4.8% (placebo 0%)
bronchitis 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
dysmenorrhoea 9.5% (placebo 2.6%)
headache 9.5% (placebo 1.3%)
conjunctivitis allergic 4.8% (placebo 0%)
NCT03199053 · Phase 3
10 mg
pharyngotonsillitis 14.3% (placebo 1.3%)
tonsillitis 14.3% (placebo 0%)
abdominal pain 0% (placebo 2.6%)
NCT03199053 · Phase 3 · combination
5 mg
headache 7.4% (placebo 1.3%)
hypertriglyceridaemia 4.9% (placebo 1.3%)
diarrhoea 3.7% (placebo 3.9%)
NCT03199053 · Phase 3
5 mg
headache 9.1% (placebo 1.3%)
nasopharyngitis 3.6% (placebo 2.6%)
anxiety 1.8% (placebo 0%)
NCT03199053 · Phase 3
5 mg
influenza 5.5% (placebo 2.6%)
abdominal pain upper 3.6% (placebo 0%)
headache 3.6% (placebo 1.3%)
NCT03199053 · Phase 3
10 mg
renal impairment 1.4% (placebo 1.7%)
acute kidney injury 1% (placebo 1.3%)
chronic kidney disease 0.9% (placebo 1.2%)
NCT01730534 · Phase 3
genital mycotic infection 13.3%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
genital mycotic infection 26.7%
mild hypoglycemia 0%
NCT02911792 · Phase 4 · registry result, not featured evidence
transcient syncope 12.5% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
transcient syncope 0% (placebo 0%)
NCT02981966 · Phase 4 · registry result, not featured evidence
nausea and vomiting 24% (placebo 0%)
genital mycosis 0% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence
nausea and vomiting 20% (placebo 0%)
genital mycosis 8% (placebo 0%)
NCT02981069 · Phase 4 · registry result, not featured evidence · combination
dysuria 12% (placebo 0%)
frequency of urination 12% (placebo 0%)
balanitis 2% (placebo 0%)
NCT02235298 · Phase 4 · registry result, not featured evidence
cold like symptoms 4.5%
genital yeast infection 4.5%
abrasion of left cornea 2.3%
NCT02973477 · Phase 4 · registry result, not featured evidence
10mg Once Daily
genital fungal infections 20.8%
NCT02682563 · Phase 4 · registry result, not featured evidence
nasopharyngitis 6.7%
toothache 6.7%
hypoglycaemia 5%
NCT02564926 · Phase 4 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 52 weeks versus 26 weeks.
  6. fTrial phases differ: Phase 4 versus Phase na.
  7. gAssessment timepoints differ: 52 weeks versus 16 weeks.
  8. hAssessment timepoints differ: 24 weeks versus 52 weeks.
  9. iPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
  10. jAssessment timepoints differ: 8 weeks versus 52 weeks.
  11. kPopulation comparability has not been reviewed for 65 of these studies.
  12. lPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

Albuminuria Progression 18.3% (n=1298) vs 24% (n=1286) placebo @ 338wk300 mg
responder rate · % of participants
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
20.2% (n=1334) vs 24% (n=1286) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
UACR Change 24.47 vs 29.3 placebo mg @ 338wk300 mg
absolute change · mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
25.5 vs 29.3 placebo mg @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
33.97 vs 43.41 placebo mg @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
eGFR -3.98 vs -5.23 placebo mL @ 338wk300 mg
absolute change · mL
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
-3.55 vs -5.23 placebo mL @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
79.9 vs 88.33 placebo mL @ 16wk
NCT02964585 · Phase 4 · registry result, not featured evidence
Weight -4.12% (n=1388) vs -0.5% (n=1398) placebo @ 338wk300 mg
percent change · % of baseline
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 33 more results
-4.7% (n=480) vs 1% (n=478) Glimepiride @ 52wk300 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.6% (n=84) vs 0% (n=85) placebo @ 26wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-0.5% (n=84) vs 0.4% (n=85) placebo @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
-3.9% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk300 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-3.1% (n=229) vs -0.1% (n=234) placebo @ 26wk300 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-3.8% (n=112) vs -0.1% (n=114) placebo @ 26wk300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-4.2% (n=360) vs -1.2% (n=355) Sitagliptin @ 26wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-4.2% (n=360) vs -1.3% (n=355) Sitagliptin @ 52wk300 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.6% (n=154) vs -0.7% (n=150) placebo @ 26wk300 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-3.9% (n=194) vs -0.6% (n=190) placebo @ 26wk300 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-2.5% (n=375) vs 0.3% (n=367) Sitagliptin @ 52wk300 mg
NCT01137812 · Phase 3 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.47% (n=1415) vs -0.5% (n=1398) placebo @ 338wk100 mg
NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-4.2% (n=479) vs 1% (n=478) Glimepiride @ 52wk100 mg
NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk100 mg
NCT01809327 · Phase 3 · registry result, not featured evidence
-2.4% (n=240) vs -0.1% (n=234) placebo @ 26wk100 mg
NCT01106651 · Phase 3 · registry result, not featured evidence
-2.8% (n=113) vs -0.1% (n=114) placebo @ 26wk100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-3.7% (n=365) vs -1.2% (n=355) Sitagliptin @ 26wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-3.8% (n=365) vs -1.3% (n=355) Sitagliptin @ 52wk100 mg
NCT01106677 · Phase 3 · registry result, not featured evidence
-2.1% (n=156) vs -0.7% (n=150) placebo @ 26wk100 mg
NCT01106625 · Phase 3 · registry result, not featured evidence
-2.8% (n=192) vs -0.6% (n=190) placebo @ 26wk100 mg
NCT01081834 · Phase 3 · registry result, not featured evidence
-2.6% (n=64) vs -1.1% (n=62) placebo @ 12wk100 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.4% (n=62) vs -1.1% (n=62) placebo @ 12wk300 mg twice daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-4.2% (n=236) vs -2.1% (n=237) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.7% (n=63) vs -1.1% (n=62) placebo @ 12wk200 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-3.2% (n=91) vs -0.6% (n=92) placebo @ 18wk150 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-3.5% (n=237) vs -2.1% (n=237) Metformin XR @ 26wk
NCT01809327 · Phase 3 · registry result, not featured evidence · combination
-2.8% (n=90) vs -0.6% (n=92) placebo @ 18wk50 mg Bid
NCT01340664 · Phase 2 · registry result, not featured evidence
-2.3% (n=63) vs -1.1% (n=62) placebo @ 12wk50 mg daily
NCT00642278 · Phase 2 · registry result, not featured evidence
-2.14% (n=75) vs -1.4% (n=65) placebo
NCT02622113 · Phase 4 · registry result, not featured evidence · combination
-3.35% (n=103) vs -1.6% (n=104) placebo @ 26wk
NCT02025907 · Phase 4 · registry result, not featured evidence
-2.13% (n=75) vs 0.24% (n=70) placebo @ 16wk
NCT02220920 · Phase 4 · registry result, not featured evidence · combination
-3.32% (n=69) vs -0.99% (n=67) placebo @ 24wk
NCT02354235 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose Change mg/dL -11.5 vs 15.3 placebo mg @ 26wk100/300 mg
absolute change · mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
show 1 more result
-16.4 vs 19.2 placebo mg @ 52wk100/300 mg
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7 5 64.9% (n=84) vs 40% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7 5 69% (n=84) vs 29.3% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 51.9% (n=84) vs 27.5% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 54.9% (n=84) vs 22.7% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <7%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 41.6% (n=84) vs 11.3% (n=87) placebo @ 26wk100/300 mg
responder rate · % of participants
Week 26: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
HbA1c Less Than 6 5 36.6% (n=84) vs 12% (n=87) placebo @ 52wk100/300 mg
responder rate · % of participants
Week 52: HbA1c <6.5%
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3
Glycemic Rescue 11.9% (n=84) vs 46% (n=87) placebo100/300 mg
responder rate · % of participants
NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3

+ 30 further endpoints in the CSV export.

Dapagliflozin

Weight -1.9 kg @ 24wk10 mg AM
absolute change · kg
No placebo or comparator arm
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
-2.06 kg @ 24wk5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.1% (n=14) vs 14.5% (n=11) placebo @ 24wk10 mg AM
responder rate · % of participants
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
26% (n=73) vs 14.5% (n=11) placebo @ 24wk10 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
26.6% (n=17) vs 14.5% (n=11) placebo @ 24wk5 mg AM
NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3
25.8% (n=63) vs 14.5% (n=11) placebo @ 24wk5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
27.2% (n=17) vs 14.5% (n=11) placebo @ 24wk2.5 mg AM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.4% (n=62) vs 14.5% (n=11) placebo @ 24wk2.5 mg PM
NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3
25.2% (n=36) vs 13.8% (n=18) placebo @ 24wk10 mg
NCT00528879 · Phase 3 · combination
14.5% (n=18) vs 13.8% (n=18) placebo @ 24wk5 mg
NCT00528879 · Phase 3 · combination
20.7% (n=29) vs 13.8% (n=18) placebo @ 24wk2.5 mg
NCT00528879 · Phase 3 · combination
HbA1c 7.0 or Less 13% (n=23) vs 5.3% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 3 Participants as posted
show 1 more result
4.3% (n=23) vs 5.3% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
HbA1c Less Than or Equal to 6.5 4.3% (n=23) vs 0% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 1 Participants as posted
show 1 more result
0% (n=23) vs 0% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 0 Participants as posted
HbA1C Decrease at Least 0.5 65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk10 mg
event count · % of participants
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
show 1 more result
65.2% (n=23) vs 15.8% (n=19) placebo @ 12wk*20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 · converted to % from 15 Participants as posted
TDDI Change Units Per -1.35 vs 1.69 placebo per day @ 12wk10 mg
absolute change · per day
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
show 4 more results
-1.16 vs 5.08 placebo per day @ 24wk10mg
NCT00673231 · Phase 3
-0.83 vs 1.69 placebo per day @ 12wk20 mg
NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3
-0.61 vs 5.08 placebo per day @ 24wk5mg
NCT00673231 · Phase 3
-1.8 vs 5.08 placebo per day @ 24wk2.5mg
NCT00673231 · Phase 3
Weight Loss 5% 33.3% (n=400) vs 2.5% (n=401) Glipizide Plus Metformin @ 52wk
responder rate · % of participants
NCT00660907 · Phase 3 · combination
OGTT 2 h Change mg/dL -34.9 vs -6 placebo mg/dL @ 24wk10 mg
absolute change · mg/dL
NCT00680745 · Phase 3 · combination
show 2 more results
-32 vs -6 placebo mg/dL @ 24wk5 mg
NCT00680745 · Phase 3 · combination
-37.5 vs -6 placebo mg/dL @ 24wk2.5 mg
NCT00680745 · Phase 3 · combination
Waist Circumference Change -0.17 vs 1.38 placebo cm @ 24wk10MG
absolute change · cm
NCT00683878 · Phase 3 · combination
show 2 more results
0.52 vs 1.38 placebo cm @ 24wk5MG
NCT00683878 · Phase 3 · combination
-2.37 vs -0.16 Glimepiride cm @ 52wk
NCT02564926 · Phase 4 · registry result, not featured evidence
HbA1c 35.3% (n=223) vs 16.6% (n=223) placebo @ 24wk
responder rate · % of participants
NCT00984867 · Phase 3
Insulin Dose Reduction 19.7% (n=194) vs 11% (n=191) placebo @ 24wk10mg
responder rate · % of participants
NCT00673231 · Phase 3
show 2 more results
16.8% (n=209) vs 11% (n=191) placebo @ 24wk5mg
NCT00673231 · Phase 3
18.1% (n=200) vs 11% (n=191) placebo @ 24wk2.5mg
NCT00673231 · Phase 3
Glycemic Control Failure 9.8% (n=194) vs 28% (n=193) placebo @ 24wk10mg
event count · % of participants
NCT00673231 · Phase 3 · converted to % from 19 Participants as posted
show 2 more results
11.4% (n=211) vs 28% (n=193) placebo @ 24wk*5mg
NCT00673231 · Phase 3 · converted to % from 24 Participants as posted
10.9% (n=202) vs 28% (n=193) placebo @ 24wk*2.5mg
NCT00673231 · Phase 3 · converted to % from 22 Participants as posted

+ 28 further endpoints in the CSV export.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Canagliflozin · Invokana

Marketed by Johnson & Johnson and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT02065791 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.

Next expected readout: December 2026 · NCT05507892 (registry estimate)

Reported efficacy

Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)

Result source: NCT03436693

Dapagliflozin · Farxiga / Forxiga

Marketed by AstraZeneca and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03036150 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)

Result source: NCT03036150

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCanagliflozinDapagliflozin
Kidney composite outcome—Not reported6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150
UACR, % change0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
eGFR slope—Not reported—Not posted · NCT05998837
Haemoglobin, change—Not reported—Not posted · NCT05998837

Kidney composite outcome

Canagliflozin
—Not reported
Dapagliflozin
6.6% vs 11.3%−4.7 vs placebon 2152NCT03036150

UACR, % change

Canagliflozin
0.6% vs 1.2%−0.6 vs placebo100mg · wk 104 · n 124NCT03436693
Dapagliflozin
-22.4% vs -1.8%−20.6 vs placebo10 mg · wk 24 · n 140NCT02547935
9 other results
  • -39.1% vs -1.8% 10 mg + 2.5 mg · wk 24 · n 151 · Phase 2/3 · primary NCT02547935
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · primary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -34.3% vs 230.3% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370

eGFR slope

Canagliflozin
—Not reported
Dapagliflozin
—Not posted · NCT05998837

Haemoglobin, change

Canagliflozin
—Not reported
Dapagliflozin
—Not posted · NCT05998837
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Canagliflozin: 4 of 4 rows · Dapagliflozin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCanagliflozinDapagliflozin
Dropout rate
0.7%100 mga
NCT02065791 · Phase 3
show 1 more result
19.5%100mg
NCT03436693 · Phase 3
—10 mga
NCT03036150 · Phase 3
show 10 more results
0.5%Dapagliflozin
NCT03036150 · Phase 3
5.5%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
3.2%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
17.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
25%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
20.7%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
9.9%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100 mga
NCT02065791 · Phase 3
show 1 more result
14.3%100mg
NCT03436693 · Phase 3
—10 mga
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
—10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
—10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
2.9%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3.9%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Serious AEs
33.5%100 mga
NCT02065791 · Phase 3
show 1 more result
27.9%100mg
NCT03436693 · Phase 3
29.5%10 mga
NCT03036150 · Phase 3
show 10 more results
—Dapagliflozin
NCT03036150 · Phase 3
8.3%10 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
7.9%10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
12.1%10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
5.6%1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
2.2%0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
1.9%10 mg
NCT03190694 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mga
hypoglycaemia 9.7% (placebo 10.3%)
urinary tract infection 9.2% (placebo 8.4%)
hypertension 6.5% (placebo 8.8%)
NCT02065791 · Phase 3
show 1 more result
100mg
nasopharyngitis 35.1% (placebo 37%)
hypoglycaemia 21.4% (placebo 20.8%)
blood glucose decreased 17.5% (placebo 14.9%)
NCT03436693 · Phase 3
10 mga
nasopharyngitis 4.3% (placebo 3.8%)
urinary tract infection 3.6% (placebo 3.7%)
hypoglycaemia 3.4% (placebo 3.3%)
NCT03036150 · Phase 3
show 9 more results
10 mg
nasopharyngitis 6.9% (placebo 4.1%)
influenza 5.5% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence
10 mg + 2.5 mg
nasopharyngitis 6.6% (placebo 4.1%)
influenza 1.3% (placebo 1.4%)
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
10 mg
hyperkalaemia 9.1% (placebo 0%)
urinary tract infection 9.1% (placebo 0%)
fall 6.1% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
brain natriuretic peptide increased 5% (placebo 0.6%)
headache 4.5% (placebo 1.1%)
metabolic acidosis 3.9% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.25 mg
headache 6.6% (placebo 1.1%)
hypertension 5.5% (placebo 0.6%)
metabolic acidosis 5.5% (placebo 1.1%)
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
10 mg
any adverse event 32.1% (placebo 25%)
NCT03190694 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Canagliflozin

eGFR 30% Decline 18.2% (n=154) vs 29.5% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR 40% Decline 10.1% (n=154) vs 13.9% (n=154) placebo @ 104wk100mg
responder rate · % of participants
NCT03436693 · Phase 3
eGFR Change mL/Min/1.73 m2 -10.39 vs -11.49 placebo mL @ 104wk100mg
absolute change · mL
NCT03436693 · Phase 3

Dapagliflozin

Time to Cardio-renal Composite Endpoint 9.2% (n=2152) vs 14.5% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 197 Participants as posted
Time to Composite Renal Endpoint 6.6% (n=2152) vs 11.3% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 142 Participants as posted
Time to CV Death or HF Hospitalization 4.6% (n=2152) vs 6.4% (n=2152) placebo
event count · % of participants
NCT03036150 · Phase 3 · converted to % from 100 Participants as posted
Overall Survival 4.7% vs 6.8% placebo
time to event · count
NCT03036150 · Phase 3
HbA1c -0.43% (n=140) vs -0.27% (n=145) placebo @ 24wk10 mg
absolute change · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.85% (n=151) vs -0.27% (n=145) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Weight -1.48% (n=144) vs -0.61% (n=148) placebo @ 24wk10 mg
percent change · % of baseline
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-0.65% (n=152) vs -0.61% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose Change mg/dL -13.1 vs -11.2 placebo mg @ 24wk10 mg
absolute change · mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-17.2 vs -11.2 placebo mg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
UACR 30 45% (n=144) vs 31.3% (n=148) placebo @ 24wk10 mg
responder rate · % of participants
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
57% (n=152) vs 31.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
HbA1c Less Than 7 15% (n=144) vs 10.3% (n=148) placebo @ 24wk10 mg
absolute value · percentage points
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
35.1% (n=152) vs 10.3% (n=148) placebo @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
Seated SBP -6.9 vs -4.1 placebo mmHg @ 24wk10 mg
absolute change · mmHg
NCT02547935 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-8.8 vs -4.1 placebo mmHg @ 24wk10 mg + 2.5 mg
NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination
eGFR -3.498 vs 6.88 placebo mL @ 12wk10 mg
absolute change · mL
NCT04595370 · Phase 2 · registry result, not featured evidence
show 3 more results
-5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · registry result, not featured evidence · combination
UACR 0.48 vs 0.72 placebo mg @ 12wk1.5 mg
absolute change · mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
0.48 vs 0.72 placebo mg @ 12wk1.5 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.52 vs 0.72 placebo mg @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination
0.52 vs 0.72 placebo mg @ 12wk0.25 mg
NCT04724837 · Phase 2 · registry result, not featured evidence · combination

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Dapagliflozin's landscape